Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 243 of 6351
-
New hope for lupus skin lesions: drug trial targets stubborn cases
Disease control OngoingIn this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus…
Phase 2/3 • Sponsor: Biogen • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for Tough-to-Treat colorectal cancer?
Disease control OngoingThe primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-…
Phase 3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Ear zap therapy: a new hope for aging hearts?
Disease control Recruiting nowHeart failure with reduced ejection fraction (HFrEF) is a major cause of mortality in United States. Aging is a major risk factor for adverse outcomes associated with HFrEF, with majority of the patient's over the age of 50, continuing to experience symptoms, reduced exercise cap…
Sponsor: University of Oklahoma • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a Dual-Action drug outsmart advanced cancers?
Disease control OngoingThis study is an open-label, multicenter, phase Ia/Ib study. The study will evaluate the safety, tolerability and preliminary efficacy of IBI363 in subjects with advanced, relapsed or metastatic solid tumors or lymphoma, determine the maximum tolerated dose (MTD) or maximum admin…
Phase 1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Radioactive injection shows promise in slowing neuroendocrine tumor growth
Disease control OngoingThis was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutetium\[177Lu\] Oxodotreotide Injection to high dose (60 mg) Octreotide LAR in patients with unresectable or metastatic, progressive, well differ…
Phase 3 • Sponsor: Sinotau Pharmaceutical Group • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
Can extra chemo before surgery beat standard rectal cancer care?
Disease control Recruiting nowThe purpose of this protocol is to compare neoadjuvant chemoradiation plus consolidation chemotherapy before surgical resection with the standard neoadjuvant chemoradiation followed by surgical resection and adjuvant chemotherapy in patients with rectal cancer.
Sponsor: Larissa University Hospital • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Hope for Alzheimer's psychosis: new drug aims to stop relapses
Disease control Recruiting nowThis is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease. The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with…
Phase 3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can your own cells ease osteoarthritis pain?
Disease control Recruiting nowThe purpose of this trial is to compare the effect of a single intra-articular injection of Lipoaspirate Concentrate vs Bone Marrow Aspirate on pain reduction and functional improvement in the treatment of the knee and hip OA.
Phase 2 • Sponsor: Grigory Karmy • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug aims to stop NMOSD attacks in its tracks
Disease control OngoingThis study will evaluate the safety and efficacy of MIL62 in patients with Neuromyelitis Optica Spectrum Disorder.
Phase 3 • Sponsor: Beijing Mabworks Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can a daily hormone shot boost natural pregnancy in couples with unexplained male infertility?
Disease control Stopped earlyThe primary purpose of this trial is to investigate whether men with idiopathic infertility (unexplained reduction of semen quality), after being treated with a daily dose of 12 µg recombinant follicle stimulating hormone (rFSH) for 6 months, can improve the chance of spontaneous…
Phase 2 • Sponsor: Ferring Pharmaceuticals • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Experimental drug DON aims to protect brains of children with cerebral malaria
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the safety of a single intravenous dose of DON in healthy adults, adults with uncomplicated malaria, and children 12 months-14 years old with clinically defined Cerebral Malaria. The main objectives are: * Evaluate the safety of a s…
Phase 1/2 • Sponsor: Douglas Postels, MD, MS • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can a new drug shield rectal cancer patients from Radiation's worst side effects?
Disease control Recruiting nowIn this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal adenocarcinoma (RA…
Phase 2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Brain device zaps seizures in Tough-to-Treat epilepsy
Disease control CompletedTo demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant idiopathic generalized epilepsy.
Sponsor: NeuroPace • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Can a Two-Drug combo in one liposome beat AML at first try?
Disease control OngoingVyxeos Vyxeos is a liposomal-encapsulated combination of cytarabine and daunorubicin, at a molar ratio of 5:1. Delivery of the 5:1 molar ratio seems to prevent antagonistic drug-drug interactions and the liposomal encapsulation increases the plasma half-life of cytarabine and dau…
Phase 2 • Sponsor: Shaare Zedek Medical Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Double-Drug attack on tough lung cancer mutation
Disease control CompletedThis study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.
Phase 1/2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Sound waves aimed at the brain: a new approach to OCD?
Disease control OngoingThis research study is to investigate the safety, feasibility, and possible therapeutic benefits of a technology called Low Intensity Focused Ultrasound (LIFU) in patients with obsessive- compulsive disorder (OCD). The device used in this study transmits high frequency sound wave…
Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could less be more? trial tests reduced radiation and chemo after surgery for HPV-Linked throat cancer
Disease control Recruiting nowThis is a trial studying patients with human papilloma virus (HPV) positive oropharyngeal cancer with tumors that can be removed via transoral surgery. Following surgery, patients will be classified as either low, intermediate, or high risk based on the characteristics of the tum…
Phase 2 • Sponsor: Heath Skinner • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Immunotherapy before surgery shows promise for certain colorectal cancers
Disease control Recruiting nowColorectal cancer (CRC) is the 2nd to 3rd most common malignant disease in developed countries, with over 1 million new cases and 500,000 deaths worldwide each year. The primary treatment for early stage CRC is surgery to remove the tumour, which is possible in 80% of patients. E…
Phase 2 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Radioactive therapy shows promise for tough prostate cancer
Disease control Recruiting nowTo determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Phase 1/2 • Sponsor: Blue Earth Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a common sedative shield aging brains from Post-Surgery delirium?
Prevention CompletedPostoperative delirium (POD) is a common surgical complication. The incidence is 10% to 22% in neurological procedures, and advanced age is a risk factor for neurological procedures. Many studies have shown that dexmedetomidine(DEX) may reduce the incidence of delirium in non-car…
Sponsor: Beijing Tiantan Hospital • Aim: Prevention
Last updated Aug 30, 2026 00:00 UTC